Spoken Alpha
AYTU BIOPHARMA, INC
Aytu BioPharma develops and commercializes prescription medications for central nervous system disorders, primarily major depressive disorder and ADHD. The company markets EXXUA (gepirone), a novel antidepressant approved by the FDA, alongside established ADHD products Adzenys and Cotempla, and pediatric allergy and fluoride-supplement products.
AYTU BIOPHARMA, INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $20.3M market cap.
Most recent reported earnings: Q4 FY2026 (Sep 21, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AYTU.
$ curl https://api.spokenalpha.com/v1/companies/AYTUFAQ
Spoken Alpha indexes AYTU's earnings call transcripts at https://spokenalpha.com/companies/AYTU. Each call links to attributed speakers and parsed analyst Q&A. AYTU BIOPHARMA, INC's own investor relations page is at https://investors.aytubio.com/.
AYTU BIOPHARMA, INC (AYTU) held its most recent earnings call on 2026-02-03, covering fiscal Q2 2026.
AYTU BIOPHARMA, INC (AYTU) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 2026-09-21 | — | $-0.22 | — | — | — | — | EODHD |
| Q3 FY2026 | 2026-05-12 | $-0.41 | $-0.42 | +2.4% | $12.4M | — | — | EODHD |
| Q2 FY2026 | 2026-02-02 | $-0.23 | $-0.49 | +53.1% | $15.2M | — | — | EODHD |
| Q1 FY2026 | 2025-11-12 | $-0.09 | $-0.19 | +52.6% | $13.9M | — | — | EODHD |
| Q4 FY2025 | 2025-09-22 | $-2.93 | $0.53 | -100.0% | $15.1M | — | — | EODHD |
| Q3 FY2025 | 2025-05-13 | $0.21 | $-0.17 | +100.0% | $18.5M | — | — | EODHD |
| Q2 FY2025 | 2025-02-11 | $0.13 | $-0.28 | +100.0% | $16.2M | — | — | EODHD |
| Q1 FY2025 | 2024-11-12 | $-0.15 | $-0.34 | +55.9% | $16.6M | — | — | EODHD |
| Q4 FY2024 | 2024-09-24 | $-0.82 | $-0.45 | -82.2% | $18.0M | — | — | EODHD |
| Q3 FY2024 | 2024-05-14 | $-0.52 | $-0.64 | +18.8% | $14.0M | — | — | EODHD |
| Q2 FY2024 | 2024-02-13 | $-0.04 | $-0.25 | +84.0% | $18.7M | — | — | EODHD |
| Q1 FY2024 | 2023-11-13 | $-1.48 | $-0.04 | -100.0% | $17.8M | — | — | EODHD |
| Q4 FY2023 | 2023-09-26 | $-0.59 | $-0.95 | +37.9% | $30.7M | — | — | EODHD |
| Q3 FY2023 | 2023-05-10 | $-1.93 | $-0.80 | -100.0% | $22.7M | — | — | EODHD |
| Q2 FY2023 | 2023-02-20 | $-1.32 | $0.20 | -100.0% | $26.3M | — | — | EODHD |
| Q1 FY2023 | 2022-11-13 | $-1.20 | $-3.60 | +66.7% | $27.7M | — | — | EODHD |
| Q4 FY2022 | 2022-09-26 | $-9.80 | $-7.40 | -32.4% | $27.4M | — | — | EODHD |
| Q3 FY2022 | 2022-05-15 | $-35.80 | $-8.20 | -100.0% | $24.2M | — | — | EODHD |
| Q2 FY2022 | 2022-02-13 | $-8.80 | $-11.60 | +24.1% | $23.1M | — | — | EODHD |
| Q1 FY2022 | 2021-11-14 | $-6.44 | $-1.60 | -100.0% | $21.9M | — | — | EODHD |
Source: EODHD. AYTU reported actuals as published; sparse fields render as —.